Orexo starts to test modia™ on patients in collaboration with ApexB.io and Magellan Rx Management
·The Covid-19 pandemic has highlighted the urgent need for additional resources to prevent overdose deaths, which have reached an all-time high[[[1]]] · modia™ can help those with opioid use disorder by providing access to quality, evidence-based interventions and behavioral health servicesMORRISTOWN, NJ, US, February 10, 2021: Orexo, a Swedish pharmaceutical company,will collaborate with ApexB.io and Magellan Rx Management to further research on the use of modia™, a digital therapeutic designed for individuals with opioid use disorder (OUD), by establishing a novel, real-world